Inhibitory B7-family molecules in the tumour microenvironment.
about
Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatmentMelanoma immunotherapy dominates the fieldA Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune CheckpointsImmune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?The role of pembrolizumab in the treatment of advanced non-small cell lung cancerImmune checkpoint blockade therapy for bladder cancer treatmentNovel immunotherapeutic approaches to the treatment of urothelial carcinomaEffector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune ResponseThe emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applicationsClinical utility of nivolumab in the treatment of advanced melanomaPredictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysisAnti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic ApproachesViro-immune therapy: A new strategy for treatment of pancreatic cancerCTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their InhibitionImmunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigationsNew developments in the management of advanced melanoma - role of pembrolizumabImmune Checkpoint Blockade: A New Paradigm in Treating Advanced CancerEvolving immunotherapy strategies in urothelial cancerImmune checkpoint blockade in hepatocellular carcinoma: current progress and future directionsImmunotherapy advances for glioblastomaTrial Watch: Immunomodulatory monoclonal antibodies for oncological indicationsLinking form to function: Biophysical aspects of artificial antigen presenting cell designCarcinoma-derived interleukin-8 disorients dendritic cell migration without impairing T-cell stimulationPrognostic value of programmed cell death-ligand 1 expression in patients with non-small-cell lung cancer: evidence from an updated meta-analysis.PD-L1 is an independent prognostic predictor in gastric cancer of Western patients.The blockade of immune checkpoints in cancer immunotherapySafety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerPD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune ResponsesSpotlight on pembrolizumab in non-small cell lung cancer: the evidence to datePD-1 and its ligands are important immune checkpoints in cancerT-Cell-Based Immunotherapy for Osteosarcoma: Challenges and OpportunitiesPD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinationsCatching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatmentImmune checkpoint therapy for pancreatic cancerAnti-programmed cell death protein-1/ligand-1 therapy in different cancersImmune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacyA2aR antagonists: Next generation checkpoint blockade for cancer immunotherapyStructural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapyMechanisms of action of therapeutic antibodies for cancer
P2860
Q26738359-5A0688FB-D289-478B-86C1-811721D5052AQ26738671-B6B627B8-4BC1-4743-A162-9A7F64D9E8F3Q26738729-5F9FE947-33B0-4902-A9E4-D0C0F26A4AF3Q26740601-C04ED569-A8F9-4156-ADB5-35F63273776DQ26744076-F20CC8FC-D2DB-4711-B4E0-C6BBB3B01EF5Q26744139-DD056D70-7B46-4AC5-9300-7FA4DDA75B40Q26744347-B9FDA081-43C8-49C1-9D28-2A41509FB7F1Q26744527-8F2515B7-8317-49E0-908D-CDEF5E6A03ECQ26747516-AB5E82B9-5F3A-4605-A90D-19E0C1E850A6Q26751268-C964485D-E096-4FFF-AE5E-639D0F65B626Q26769728-F9C708DC-81D0-4B3D-9C32-73950F1FA13EQ26774312-3FE62196-7E9F-42D2-9871-4768976250C4Q26774641-A89B0B8F-84E2-4542-8328-BAD0F4F50250Q26777563-75FAB72D-4D92-4088-8ED5-54E50876AEC2Q26781038-BEAB726C-A0FD-4040-A444-A42E2599E709Q26781931-0FCFF2CF-CE27-4814-A4E7-49FDE59CF591Q26795509-57168DD7-0AC2-4F86-8747-3A127C404CF7Q26823557-9E01030E-5B96-44F6-AE0F-0BB413951CD4Q26865859-949E4044-0D9B-4B86-A5E3-A4058A656930Q26866513-9E44E6C3-DCEC-43F1-8594-99DD0085DAC0Q26996518-C18063A4-AA70-420B-B652-0254889B1092Q27002652-8619CFDA-22D4-4BAD-B99C-2EB1335C31D8Q27349546-CBA95DD0-D788-4D8B-AE7A-6CA608A73EF6Q27853291-FA8D28D8-BBF2-426C-B4D3-4880BE90F59FQ27853364-87CBCC84-6579-4E03-96EE-23163C46CC62Q27860852-05D3AA8F-72F4-4D57-BC30-B94024F3D553Q27860857-F57B8826-07A0-4898-88B2-31D7523D298DQ28067141-52BF7E2D-F09F-45A0-9AB1-AE29B12FF088Q28067610-88C5B95F-261B-4343-A055-334D61613456Q28069485-194D03A1-9465-450C-A86C-F7F2A0F24B5AQ28074619-7C8484BA-7C57-4E8F-B6EF-B988D8D68AC9Q28075712-FB403AA6-71CA-460C-B487-4A460C1489E2Q28076071-59488265-3332-4836-B85F-59F70F80541CQ28076294-ECBEDF95-077F-4C0E-9850-6E7FDCF44537Q28078390-B12AB90B-9C85-4349-9E01-44AFF96B0004Q28082259-522CA0D5-3028-439D-8C44-D4CCAC67F40EQ28082914-7065A647-890F-4A3C-A4E1-382BE2BDBE13Q28087576-3903BAC7-1EE9-4E04-A2F5-FA6470A6533EQ28314934-D92A2F7A-B39C-4A2A-90D8-7F2E702C1C7BQ28385366-11C89DDF-FF62-4962-A8AB-C95573DD6540
P2860
Inhibitory B7-family molecules in the tumour microenvironment.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
gotara zanistî
@ku-latn
scientific article published on June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
name
Inhibitory B7-family molecules in the tumour microenvironment.
@en
Inhibitory B7-family molecules in the tumour microenvironment.
@nl
type
label
Inhibitory B7-family molecules in the tumour microenvironment.
@en
Inhibitory B7-family molecules in the tumour microenvironment.
@nl
prefLabel
Inhibitory B7-family molecules in the tumour microenvironment.
@en
Inhibitory B7-family molecules in the tumour microenvironment.
@nl
P356
P1476
Inhibitory B7-family molecules in the tumour microenvironment.
@en
P2093
Lieping Chen
Weiping Zou
P304
P356
10.1038/NRI2326
P577
2008-06-01T00:00:00Z